Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

Jamie Mafdali of South Florida was hit with a cancer double-whammy three years ago. Shortly after her mother began treatment ...

To lose weight, Mafdali’s endocrinologist suggested GLP-1 receptor agonists: a new, enormously popular class of injectable weight-loss drugs known as semaglutides. They’re sold under brand names like ...

A randomized, placebo-controlled clinical trial is underway called Valacyclovir Treatment of Alzheimer’s Disease but results ...

The molecules found in Ozempic and Mounjaro could be the secret to curing Alzheimer’s and heart disease, explains ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

What else does weight-loss drug Ozempic do? 5 unexpected health benefits - Emerging scientific research indicates that ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

Patients will lose access to cheaper versions of the blockbuster drugs after the agency shuts down the multibillion-dollar industry now that the drug shortage has ended. Also in the news: Eli Lilly's ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.